Novartis
Ticker > Company >

Novartis share price

Novartis India Ltd.

NSE: NOVARTIND BSE: 500672 SECTOR: Trading  30k   43   5

817.00
-8.30 (-1.01%)
BSE: 25 Apr 04:01 PM

Price Summary

Today's High

₹ 840.05

Today's Low

₹ 801.1

52 Week High

₹ 1248

52 Week Low

₹ 744.95

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 2017.24 Cr.

Enterprise Value

₹ 1421.18 Cr.

No. of Shares

2.47 Cr.

P/E

23.38

P/B

2.67

Face Value

₹ 5

Div. Yield

3.06 %

Book Value (TTM)

₹  305.66

CASH

₹ 596.08 Cr.

DEBT

₹ 0.02 Cr.

Promoter Holding

70.68 %

EPS (TTM)

₹  34.94

Sales Growth

-11.53%

ROE

11.21 %

ROCE

16.35%

Profit Growth

-17.58 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-11.53%
3 Year-4.22%
5 Year-7.35%

Profit Growth

1 Year-17.58%
3 Year59.74%
5 Year10.47%

ROE%

1 Year11.21%
3 Year8.25%
5 Year5.8%

ROCE %

1 Year16.35%
3 Year10.82%
5 Year8.77%

Debt/Equity

0

Price to Cash Flow

17.79

Interest Cover Ratio

83.443

CFO/PAT (5 Yr. Avg.)

0.484314906630833

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 70.68 0.00
Dec 2024 70.68 0.00
Sep 2024 70.68 0.00
Jun 2024 70.68 0.00
Mar 2024 70.68 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 59.7401583865764% for the Past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 83.443.
  • The company has an efficient Cash Conversion Cycle of -22.5777 days.
  • Company has a healthy liquidity position with current ratio of 2.3557.
  • The company has a high promoter holding of 70.68%.

 Limitations

  • The company has shown a poor revenue growth of -4.22089255009929% for the Past 3 years.
  • Company has contingent liabilities of 398.38 Cr.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
Net Sales 84.54 81.17 92.29 87.1 93
Total Expenditure 64.77 69.96 68.32 69.14 67.42
Operating Profit 19.77 11.21 23.97 17.96 25.58
Other Income 21.96 10.42 10.41 10.32 10.6
Interest 0.16 0.16 0.15 0.14 0.36
Depreciation 0.26 0.14 0.55 0.58 0.53
Exceptional Items 0 0 0 0 0
Profit Before Tax 41.31 21.33 33.68 27.56 35.29
Tax 14.74 6.65 7.94 7.15 9.84
Profit After Tax 26.57 14.68 25.74 20.41 25.45
Adjusted EPS (Rs) 10.77 5.95 10.43 8.27 10.31

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 438.25 381.35 399.87 378.74 335.07
Total Expenditure 426.51 355.66 373.12 313.66 269.81
Operating Profit 11.74 25.69 26.75 65.08 65.26
Other Income 36.43 34.19 33.55 58.11 61.68
Interest 6.39 7.68 4.83 1.75 1.49
Depreciation 13.14 12.16 9.65 6.06 2.61
Exceptional Items 0 0 -49.64 0 0
Profit Before Tax 28.64 40.04 -3.82 115.38 122.84
Tax 18.56 19.14 -0.1 12.02 37.65
Net Profit 10.08 20.9 -3.72 103.36 85.19
Adjusted EPS (Rs.) 4.08 8.47 -1.51 41.88 34.52

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 12.34 12.34 12.34 12.34 12.34
Total Reserves 708.39 698.85 679.36 763.32 732.48
Borrowings 0 0 0 0 0
Other N/C liabilities 99.38 1130.65 984 1007.77 716.25
Current liabilities 416.93 357.26 334.47 268.26 399.83
Total Liabilities 1237.04 2199.1 2010.17 2051.69 1860.9
Assets
Net Block 76.28 63.91 23.65 19.25 6.94
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 137.84 1186.01 1148.65 1240.75 903.63
Other N/C Assets 25.65 26.83 12 5.63 8.44
Current Assets 997.27 922.35 825.87 786.06 941.89
Total Assets 1237.04 2199.1 2010.17 2051.69 1860.9
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 28.64 40.04 -3.82 115.38 122.84
Adjustment -11.8 -4.98 -5.64 -48.92 -56.75
Changes in Assets & Liabilities -1.85 -69.08 66.72 -24 9.04
Tax Paid -38.13 -35.19 -18.59 2.34 38.27
Operating Cash Flow -23.14 -69.21 38.67 44.8 113.4
Investing Cash Flow 55.91 95.16 87.04 -153.25 33.13
Financing Cash Flow -41.41 -36.8 -35.63 -30.48 -120.99
Net Cash Flow -8.64 -10.85 90.08 -138.93 25.54

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 70.68 70.68 70.68 70.68 70.68
novartis ag 70.68 70.68 70.68 70.68 70.68
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 29.32 29.32 29.32 29.32 29.32
atul limited 1.52 1.52 1.52 1.52 1.52
investor education and pr... 0.63 0.63 - 0.69 0.69
llp 0.37 0.30 0.31 0.30 0.37
investor education and pr... - - 0.63 - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Novartis - Quaterly Results 28 Jan, 1:18 PM Novartis - Quaterly Results 28 Jan, 1:18 PM Novartis - Quaterly Results 28 Jan, 1:18 PM Novartis - Quaterly Results 25 Oct, 1:13 PM Novartis - Quaterly Results 25 Oct, 1:13 PM Novartis - Quaterly Results 25 Oct, 1:13 PM Novartis - Quaterly Results 29 Jul, 1:30 PM Novartis - Quaterly Results 29 Jul, 1:30 PM Novartis - Quaterly Results 29 Jul, 1:30 PM Novartis India informs about loss of share certificate 4 Jul, 5:29 PM Novartis India informs about loss of share certificate 15 May, 5:06 PM Novartis India informs about board meeting outcome 10 May, 5:09 PM Novartis - Quaterly Results 10 May, 4:09 PM Novartis - Quaterly Results 10 May, 4:09 PM Novartis - Quaterly Results 10 May, 4:09 PM Novartis India informs about change in management 8 May, 5:23 PM Novartis India informs about details of loss of certificate 19 Mar, 2:50 PM Novartis India informs about loss of share certificate 28 Feb, 2:55 PM Novartis India informs about loss of share certificate 27 Feb, 11:40 AM Novartis India informs about loss of share certificate 17 Feb, 12:35 PM Novartis India informs about outcome of board meeting 17 Feb, 11:05 AM Novartis India informs about details of loss of certificate 9 Feb, 5:04 PM Novartis India informs about newspaper publication 27 Jan, 9:44 AM Novartis - Quaterly Results 25 Jan, 2:55 PM Novartis - Quaterly Results 25 Jan, 2:55 PM Novartis - Quaterly Results 25 Jan, 2:55 PM Novartis India informs about details of loss of certificate 6 Jan, 3:33 PM Novartis India informs about loss of share certificate 2 Jan, 2:20 PM Novartis India informs about issuance of duplicate share certificate 21 Dec, 4:52 PM Novartis India informs about details of loss of certificate 13 Dec, 12:53 PM Novartis India informs about details of loss of certificate 12 Dec, 4:58 PM Novartis India informs about details of loss of certificate 25 Nov, 3:21 PM Novartis India informs about details of loss of certificate 22 Nov, 4:11 PM Novartis - Quaterly Results 27 Oct, 3:12 PM Novartis - Quaterly Results 27 Oct, 3:12 PM Novartis - Quaterly Results 27 Oct, 3:12 PM Novartis India informs about closure of trading window 30 Sep, 4:23 PM Novartis India submits board meeting intimation 30 Sep, 3:47 PM Novartis India informs about loss of share certificate 20 Sep, 2:28 PM Novartis India informs about loss of share certificate 12 Sep, 10:28 AM Novartis India informs about loss of share certificate 28 Aug, 4:14 PM Novartis India informs about loss of share certificate 25 Aug, 12:11 PM Novartis India informs about loss of share certificates 14 Aug, 2:41 PM Novartis India informs about details of loss of certificate 11 Aug, 1:50 PM Novartis India informs about details of loss of certificate 9 Aug, 1:03 PM Novartis - Quaterly Results 26 Jul, 2:52 PM Novartis - Quaterly Results 26 Jul, 2:52 PM Novartis - Quaterly Results 26 Jul, 2:52 PM Novartis India informs about compliances-certificate 5 Jul, 4:31 PM Novartis India informs about loss of share certificate 3 Jul, 2:24 PM

Novartis Stock Price Analysis and Quick Research Report. Is Novartis an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Novartis stock price today is Rs 672.25. Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Novartis . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Novartis has a PE ratio of 19.2378134282656 which is high and comparatively overvalued .

  • Share Price: - The current share price of Novartis is Rs 672.25. One can use valuation calculators of ticker to know if Novartis share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Novartis has ROA of 4.3547 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Novartis has a Current ratio of 2.3557 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Novartis has a ROE of 11.2054 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Novartis has a Debt to Equity ratio of 0 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Novartis has reported revenue growth of -11.5303 % which is poor in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Novartis for the current financial year is 19.4765272928045 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Novartis is Rs 25 and the yield is 3.0652 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Novartis is Rs 34.9442 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Novartis in Ticker for free. Also, one can get the intrinsic value of Novartis by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Novartis

Novartis India Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Novartis India Ltd. is a leading pharmaceutical company in India. It is a subsidiary of the global healthcare company Novartis AG. Novartis India has been operating in the country for several decades and has established itself as a trusted provider of high-quality medicines.

Novartis India Ltd. - Share Price

Stay updated with the latest share price of Novartis India Ltd. Our website provides real-time stock prices along with historical data. Our pre-built screening tools allow you to analyze the share price performance of Novartis India over different time periods.

Novartis India Ltd. - Balance Sheet

Access the balance sheet of Novartis India Ltd. on our website. Our premium features enable fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools help long-term stock investors gain insights into the financial health of the company.

Novartis India Ltd. - Annual Report

Download the annual reports of Novartis India Ltd. from our website. The annual reports provide a comprehensive overview of the company's performance, financials, and strategic initiatives. They are valuable resources for investors to assess the company's long-term prospects.

Novartis India Ltd. - Dividend

Track the dividend history of Novartis India Ltd. on our website. Dividends are an important consideration for many investors looking for stable income from their investments. Novartis India regularly evaluates and announces dividends to reward its shareholders.

Novartis India Ltd. - Quarterly Results

Stay informed about the quarterly results of Novartis India Ltd. Our website provides access to the latest financial reports and insights from earnings calls. These reports help investors track the company's performance and make informed investment decisions.

Novartis India Ltd. - Stock Price

Analyze the stock price movement of Novartis India Ltd. on our website. Our pre-built screening tools and price charts allow investors to track the stock's historical performance and identify potential investment opportunities.

Novartis India Ltd. - Price Chart

Visualize the price chart of Novartis India Ltd. on our website. Price charts provide a graphical representation of the stock's price movement over time, helping investors spot trends, patterns, and potential support and resistance levels.

Novartis India Ltd. - News

Access the latest news updates about Novartis India Ltd. Our website provides a curated feed of news articles and press releases related to the company. Stay informed about the latest developments that may impact your investment decisions.

Novartis India Ltd. - Concall Transcripts

Download the concall transcripts of Novartis India Ltd. from our website. Concall transcripts are valuable resources that provide insights into the company's performance, management commentary, and future outlook as discussed during the earnings calls.

Novartis India Ltd. - Investor Presentations

Find investor presentations of Novartis India Ltd. on our website. Investor presentations offer a comprehensive overview of the company's strategy, financials, and operational highlights. These presentations are useful for investors to understand the company's business and investment potential.

Novartis India Ltd. - Promoters

Learn about the promoters of Novartis India Ltd. Promoters play a crucial role in the company's management and decision-making process. Our website provides information about the promoters and their contribution to the company's growth.

Novartis India Ltd. - Shareholders

Explore information about the shareholders of Novartis India Ltd. Shareholders play a significant role in the company's ownership and governance. Our website provides insights into the major shareholders of Novartis India and their stake in the company.

By providing comprehensive stock analysis tools, access to key financial reports, and curated news updates, our website aims to empower long-term stock investors in making informed decisions regarding Novartis India Ltd. Stay updated with the latest information and leverage our premium features for fair value calculations and in-depth analysis. 

Novartis India's Equity Structure

Novartis India has maintained a consistent share capital of Rs 12.34 Cr from March 2020 to March 2024. This reflects the company's stable equity base over the years without any dilution or increase in share capital, which can be a positive sign for investors looking at the company's equity stability.

Trend in Novartis India's Reserves

The reserves of Novartis India showed some fluctuations, decreasing from Rs 708.39 Cr in March 2020 to Rs 679.36 Cr in March 2022, before rising to Rs 763.32 Cr in March 2023 and then slightly dropping to Rs 732.48 Cr by March 2024. This indicates variations in the company’s retained earnings over the years.

Debt-Free Status of Novartis India

Remarkably, Novartis India has maintained a debt-free status from March 2020 to March 2024. This is quite significant as it reflects the company's financial prudence and strong liquidity position, making it a noteworthy point for investors analyzing the financial health of the company.

Changes in Novartis India's Liabilities and Assets

The company witnessed a significant rise in other non-current liabilities from Rs 99.38 Cr in March 2020 to a peak of Rs 1,130.65 Cr in March 2021, before settling at Rs 716.25 Cr by March 2024. Parallelly, the current assets saw a decline but recovered to Rs 941.89 Cr by March 2024, indicating dynamic asset management.

Novartis India's Loans and Advances

Loans and advances drastically increased from Rs 137.84 Cr in March 2020 to Rs 1,186.01 Cr in March 2021 and experienced variations before adjusting to Rs 903.63 Cr by March 2024. This shift reflects significant changes in the company's financial positioning and lending activities over the years.

This analysis is for the Standalone Balance Sheet of Novartis India. Analyzing these financial statements alongside broader market trends or sector performances can offer investors deeper insights into the company's standing within the pharmaceutical industry.

Read More
X